Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice

Eckstein, Michael; Barenholz, Yechezkel; Bar, Laure; Segal, Esther

doi:10.1016/s0264-410x(96)00137-5

Cited by 27 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rpl10Ep and Efb1p are two of 61 proteins coinduced in C. albicans cells exposed to human blood and are, therefore, likely to also be induced in our systemic candidiasis model [52]. There is some evidence to support the immunogenic role of ribosomal proteins in very different microorganisms including C. albicans [53], Brucella abortus [54], Neospora caninum and Toxoplasma gondii [55], Babesia microti [56,57], Plasmodium falciparum [58], and S. gonococci [59], as well as in parasites such as Leishmania [60]. It is interesting to note that the homologues of C. albicans Rpl10E protein of several microorganisms have been confirmed to confer protection used as vaccines against their corresponding diseases [55,57,58,61].…”

Section: Search For New Antigenic Proteins As Putative Candidates Formentioning

confidence: 85%

Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice

et al. 2008

View full text Add to dashboard Cite

Systemic candidiasis remains a major cause of disease and death, particularly among immunocompromised patients. The cell wall of Candida albicans defines the interface between host and pathogen and surface proteins are major elicitors of host immune responses during candidiasis. The C. albicans ecm33 mutant (RML2U) presents an altered cell wall, which entails an increase in the outermost protein layer. Vaccination of BALB/c mice with RML2U mutant protected them from a subsequent lethal infection with virulent strain SC5314 in a systemic candidiasis model. Using immunoproteomics (2-DE followed by Immunoblotting) we detected 29 immunoreactive proteins specifically recognized by antibodies from vaccinated mice sera, six of which are described as immunogenic for the first time (Gnd1p, Cit1p, Rpl10Ep, Yst1p, Cys4p, Efb1p). Furthermore, identification of wild type and mutant cell surface proteome (surfome), confirmed us that the mutant surfome presented a larger number of proteins than the wild type. Interestingly, proteins exclusively identified in the mutant surfome (Met6p, Eft2p, Tkl1p, Rpl10Ep, Atp1p, Atp2p) were also detected as immunogenic, supporting the idea that their surface location enhances their immunoprotective capacity.

show abstract

Section: Search For New Antigenic Proteins As Putative Candidates Formentioning

confidence: 85%

Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In experimental candidiasis, the best protective effects have been achieved by immunization with viable cells from virulent (Cassone et al, 1995;Giger et al, 1978;Mourad & Friedman, 1961) strains of Candida albicans, while immunization with killed cells or subcellular components of the organism has been moderately successful (Banerjee et al, 1985;Eckstein et al, 1997;Levy et al, 1985;Mencacci et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein

Tavares¹,

Ferreira

Arala-Chaves

2003

Microbiology

View full text Add to dashboard Cite

“…The best protective effects observed to date have been stimulated by immunization with viable cells from virulent (26,40) or avirulent (3) strains of C. albicans. Killed cells or subcellular components have been moderately successful (2,20,35,39,49). Although some evidence has accumulated that antibody to specific immunogens, e.g., hsp90 (38), hsp75, or non-hsp96 (13), is protective systemically, much of the evidence is circumstantial.…”

mentioning

confidence: 99%

Effectiveness of a Vaccine Composed of Heat-KilledCandida albicansand a Novel Mucosal Adjuvant, LT(R192G), against Systemic Candidiasis

et al. 1999

View full text Add to dashboard Cite

The incidence of fungal infections caused by the opportunistic yeast Candida albicans has increased significantly in recent years. The ability to vaccinate selected patients against the organism would be advantageous. In this paper we describe a potential anti-C. albicans vaccine consisting of heat-killed C. albicans (HK-CA) in combination with the novel mucosal adjuvant LT(R192G), a genetically detoxified form of the heat-labile toxin of enterotoxigenic Escherichia coli. Groups of male CBA/J mice were immunized intranasally on three occasions at weekly intervals with 2 × 107 HK-CA per dose, alone or in conjunction with 10 μg of LT(R192G) per dose. Two weeks following the last application of antigen, some animals were challenged intravenously (i.v.) with 104, 105, or 106 viable C. albicans to assess protection as measured by survival and/or culture. Some groups of animals were footpad tested withC. albicans mannan to assess delayed-type hypersensitivity (DTH), and all the animals were bled for antibody assays. In two independent studies, all the animals immunized with HK-CA plus LT(R192G) were able to eradicate 104 C. albicans completely, as determined by kidney culture 4 weeks after challenge. Animals immunized with HK-CA only had reduced levels of C. albicans compared to the adjuvant or saline-only control. Greatly enhanced survival was observed when mice immunized with HK-CA plus LT(R192G) were challenged with 105 live C. albicans as well. Animals immunized with HK-CA plus LT(R192G) developed a significant DH response, while those given HK-CA alone developed only marginal DH responses. High immunoglobulin G (IgG) levels to cytoplasmic antigens developed in mice immunized with HK-CA plus LT(R192G), but they were found only after i.v. challenge. Addition of adjuvant shifted the antibody isotype production in i.v.-challenged animals to a response dominated by IgG2a. Clearly, intranasal immunization with killedC. albicans in conjunction with LT(R192G) afforded significant levels of protection. This novel approach offers new possibilities for the development of an effective vaccine against candidiasis for use in humans.

show abstract

Liposomes containing Candida albicans ribosomes as a prophylactic vaccine against disseminated candidiasis in mice

Cited by 27 publications

References 21 publications

Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice

Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice

Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein

Effectiveness of a Vaccine Composed of Heat-KilledCandida albicansand a Novel Mucosal Adjuvant, LT(R192G), against Systemic Candidiasis

Contact Info

Product

Resources

About